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background: The response to beta blockers in chronic heart failure (CHF) patients is heterogeneous according to genetic variations in the 
adrenergic signaling genes. This study investigated the association between the coding region variations of adrenergic receptor genes and 
therapeutic effect of beta blocker.
Methods: Association between Beta adrenergic receptor polymorphism and Bisoprolol therapy in heArt failure (ABBA) study enrolled 100 CHF 
patients (NYHA class II-III) with reduced left ventricular ejection fraction < 45%. Enrolled patients started bisoprolol 1.25mg once daily, and the 
dose was up-titrated to the maximally tolerable dose. Patients were genotyped for ADRB1 Arg389Gly (rs1801253). Genotypic results were double-
blinded to the patients as well as investigators throughout the study period.
results: 1) At position 389 of the beta-1 adrenergic receptor (ADRB1), 53 patients were homozygous for the Arg genotype, 5 patients were 
homozygous for the Gly genotype and 25 patients were heterozygous. The observed minor Gly allele frequency was 21% and no deviation from 
Hardy-Weinberg equilibrium was seen in the genotype distribution of Arg389Gly (p=0.75). 2) ABRB1 Arg389Arg genotype group showed better 
tolerability to bisoprolol compared with Gly389X (Gly389Arg+Gly389Gly) group with significantly larger dose (5.19±2.66mg vs 3.95±2.19mg, 
p=0.046). 3) Following 12 weeks’ bisoprolol therapy, LVEF was significantly improved from 32.6±7.8% to 41.3±10.4% in overall (p<0.0001). Left 
ventricular volume was significantly reduced by 18% in Arg389Arg group (p<0.0001) compared with insignificant 7% reduction in Gly389X group 
(111.5±42.9ml), and there was significant difference in left ventricular volume reduction between two groups (p=0.03). 4) Exercise capacity 
increased with marginal significance in Arg389Arg group (+21±90 m, p=0.09), whereas there was essentially no change in Gly389X group (-1±93 m, 
p=0.96).
conclusion: In heart failure patients, ABRB1 Arg389Arg genotype showed better tolerability and reverse remodeling effect to bisoprolol. The 
findings of this study implicate the potential of individually tailoring of beta blocker therapy according to genotypes.
